Investment
Features
FeesSafety
Academy
More
Pluang+

Compare L3Harris Technologies Inc (LHX) vs Zoetis Inc (ZTS) Price & Performance

L3Harris Technologies IncTrade
Zoetis IncTrade

Price performance (Past 24H)

Key statistics

L3Harris Technologies Inc vs Zoetis Inc — how do they compare? L3Harris Technologies Inc trades at $236.8 (market cap $44.12B), while Zoetis Inc trades at $74.76 (market cap $30.20B). The key difference: L3Harris Technologies Inc is the larger of the two by market cap, and Zoetis Inc pays the higher dividend (2.9%). Which is the better fit depends on your goals — on Pluang, investors hold L3Harris Technologies Inc for 56 Days and Zoetis Inc for 70 Days on average.

LHXZTS
Market Cap
$44.12B$30.20B
Volume
1,202,8526,175,327
Sector
IndustrialsHealth
52-Week High
$378.48$147.53
52-Week Low
$233.63$69.09
Typical Hold Time
56 Days70 Days
Enterprise Value
$54.56B$37.76B
Dividend Yield
2.11%2.9%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

L3Harris Technologies Inc

LHX trades at $236.97, up 1.43% today, with a bearish technical signal despite strong fundamentals. The company reported revenue of $21.87B in 2025, with net income of $1.61B and improving profit margins. Recent contract wins, including a $6B THAAD propulsion deal with Lockheed Martin, highlight growth prospects. However, multiple law firm investigations into the company have emerged in September 2026, creating investor uncertainty.

The outlook is mixed: analyst consensus is bullish with a $340 price target, but technical indicators and legal overhangs pose risks. Earnings beats in recent quarters support fundamental strength, yet sentiment is tempered by bearish momentum and potential legal liabilities. Upside depends on contract execution and resolution of investigations.

Zoetis Inc

Zoetis (ZTS) trades at $74.77, up 4.5% with strong profitability metrics including 71.67% gross margins and 27.69% net income margin. The stock shows mixed technical signals with bullish oscillators but bearish moving averages, trading near resistance at $75. Recent earnings show beats in Q4 2025 and Q2 2026 but a miss in Q1 2026, with Q3 2026 results pending. The company maintains robust cash flow generation despite competitive pressures in the U.S. companion animal market.

Zoetis presents a compelling value opportunity with a P/E of 11.92 below industry averages, though near-term headwinds from pet care weakness and competition persist. Analyst consensus targets $87.33 with no sell ratings, suggesting 17% upside potential. Key risks include ongoing margin pressure and market share challenges, but strong international growth and dividend sustainability support long-term bullish thesis.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

LHX
0% Buy100% Sell
Avg holding period · 56 Days
ZTS

No sentiment data available yet.

Top news

Latest headlines on both assets

About L3Harris Technologies Inc

L3Harris Technologies was created in 2019 from the merger of L3 Technologies and Harris, two defense contractors that provide products for the command, control, communications, computers, intelligence, surveillance, and reconnaissance (C4ISR) market. The firm also has smaller operations serving the civil government, particularly the Federal Aviation Administration's communication infrastructure, and produces various avionics for defense and commercial aviation.

Read more on LHX →

About Zoetis Inc

Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.

Read more on ZTS →